USPatent applicationPatented

Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability

Granted 27 Apr 2010 · 2 office actions

Life of the application

19 dated events
⤢ drag to zoom20042006200820102012201420162018202020222024ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Tablets of a poorly compressible drug are made by direct compression using a binder composition which is a polymer, preferably a copolymer of polyvinylpyrrolidone (PVP) and vinyl acetate (VA), having a defined glass transition temperature (Tg), admixed with a plasticizer, e.g. an organic ester or polyol, which reduces the Tg of the copolymer by at least 10° C. The binder composition and the drug are directly compressed into a tablet of predetermined hardness and friability, and at an acceptable compression force.

Description

11 parts
›CROSS-REFERENCE TO RELATED PATENT APPLICATION

This application is based upon Provisional Application Ser. No. 60/468,001 filed May 5, 2003.

›BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to direct compression of poorly compressible drugs, and, more particularly, to a new and improved binder composition for such drugs, which enables mixtures thereof to be processed into drug tablets of desired hardness and friability by direct compression, and at an acceptable compression force.

2. Description of the Prior Art

Poorly compressible drugs such as naproxen and acetaminophen are currently made into tablets by wet granulation. However, it would be advantageous to provide a method of forming tablets of such drugs by direct compression, which is a more commercially advantageous process.

›SUMMARY OF THE INVENTION

Tablets of a poorly compressible drug are made by direct compression using a binder composition which is a mixture of a polymer, e.g. a copolymer of polyvinylpyrrolidone (PVP) and vinyl acetate (VA), hydroxypropyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone, having a defined glass transition temperature (Tg), and an effective amount of a plasticizer therewith, to reduce the Tg of said copolymer by at least 10° C. The binder composition and drug are admixed, and formed into a tablet by direct compression at an acceptable compression force. The resultant tablet has an advantageous hardness and friability.

The preferred copolymer is 60 wt. % PVP and 40% VA having a Tg of 106° C., and the plasticizer reduces the Tg of this copolymer by at least 20° C. when present in admixture therewith in an amount of about 1-25 wt. %, preferably 5-15%. Representative plasticizers include polyethylene glycol, triethyl citrate, acetylated fatty acid glycerides, castor oil, dibutyl phthalate, diethyl phthalate, dibutyl sebacate, glycerol, glycerol monostearate, glyceryl triacetate, polyoxyethylene/polyoxypropylene copolymers and propylene glycol. Preferred plasticizers are organic esters and polyols, for example, triethyl citrate and polyethylene glycol.

In general, the binder composition is a free-flowing powder having an average particle size of about 30-90μ.

A typical poorly compressible drug in the invention is naproxen or acetaminophen.

The process of the invention is carried out by direct compression of the admixture of about 1-25 wt. % of the binder composition and at least 50%, preferably 50-90 wt. % of the drug, the rest being other excipients. Direct compression at about 3000-7000 lbs. provides a tablet having a hardness of at least about 8 Kp, generally 8-20 Kp, and a friability of about less than 3%, preferably 1-3%.

›DETAILED DESCRIPTION OF THE INVENTION

The invention will now be illustrated in more detail by reference to the following examples.

The test for efficacy of selected polymer and plasticizer is described in the following Example 1, wherein an aqueous dispersion of the components is prepared, mixed well, and dried on a substrate. Then the glass transition temperature Tg is determined and compared to a control (without plasticizer). The criteria for efficacy is a reduction in Tg (with plasticizer) by at least 10° C.

›Examples7
›Example 1

Aqueous dispersions of a binder composition of PVP/VA copolymer (60:40 by wt.) and plasticizer were spray dried in a laboratory scale spray dryer. The resultant powders were collected in a plastic bag. The glass transition temperature for each composition was determined and compared to copolymer without plasticizer (control). The results are shown in Table 1 below.

The data in Table 1 demonstrates that the plasticizer reduced the Tg of the copolymer by at least 10° C., and up to 27° C.

›Example 2

Free flowing powders of a binder composition of PVP/VA (60:40) plasticized with added PEG 4000 (5 and 10% w/w) or triethyl citrate (TEC) (5 and 10% w/w), having a particle size of 30μ, and a poorly compressible drug (acetaminophen) were prepared at a wt. ratio of 75:25 drug:binder composition. Then 0.5% silica and 0.5% lubricant were added and the mixture was compressed at a compression force of (lbs) 3000, 5000 or 7000. The hardness and friability values of the resultant tablets are shown in Table 2 below.

The data in Table 2 demonstrates that the drug tablet plasticized with PEG or TEC had a hardness value of 13.9 to 26.1 kP, as compared to only 5 to 7.4 kP for the control. Also friability was reduced from 3-9% for control (copolymer without plasticizer) to only 0.27 to 0.64% with added plasticizer.

›Example 3

The properties of the binder compositions of the invention were determined and compared to the copolymer itself as a control. The test powders were prepared in laboratory apparatus (composition A) or in a production minor spray dryer (5′×5′) using a rotary wheel atomizer with and without an air broom device (composition B). These copolymers were used as controls, or admixed with plasticizer (composition C) and (composition D). Drying was carried out at an inlet temperature of 150° C., an outlet temperature of 80° C. and a feed temperature of 50° C. The results are given in Table 3 below.

The results in Table 3 show that the binder compositions C and D reduced the Tg of the control copolymers A or B by >20° C., decreased the particle size of the copolymer powders.

›Example 4

Typical formulations of binder composition and drug ready for direct compression into tablets are given in Table 4 below.

›Example 5

Table 5 below shows the hardness and friability properties of tablets obtained by direct compression of the formulations of Example 4 at various compression forces.

The results in Table 5 show that the binder compositions of the invention provide hard tablets with low friability, even with a high amount of drug (77%) present in the tablet.

›Example 6

Tablets can be prepared as above using hydroxypropyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone as the polymer component in the binder composition. Similar results are obtained.

›Example 7

Tablets can be prepared as above using the following as plasticizers: polyethylene glycol, triethyl citrate, acetylated fatty acid glycerides, castor oil, dibutyl phthalate, diethyl phthalate, dibutyl sebacate, glycerol, glycerol monostearate, glyceryl triacetate, polyoxyethylene/polyoxypropylene copolymers and propylene glycol. Similar results are obtained.

While the invention has been described with particular reference to certain embodiments thereof, it will be understood that changes and modifications may be made which are within the skill of the art. Accordingly, it is intended to be bound only by the following claims, in which:

›Tables in the description — 2
TABLE 1
Binder CompositionTg (° C.)
Copolymer (Control)106
Copolymer w/5% PEG* 400090
Copolymer w/10% PEG* 400079
Copolymer w/10% TEC**82
*polyethylene glycol
**triethyl citrate
TABLE 5 — Composition → Binder
CopolymerComposition
PropertyABCD
Hardness
3000 K3.17.910.27.5
50004.18.411.79.2
70004.47.58.99.4
Friability
300018.02.12.72.5
500011.62.11.72.0
700010.52.21.42.2

Claims as granted

17 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

8 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K9/20
  • A61K9/26
  • A61K9/22
USPC · US Patent Classification
424/469424/464424/465424/468424/489

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom2004200520062007200820092010USPTOApplicantNon-final rejectionResponse after non-finalResponse after finalNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
6.7 y
2,447 days filing → grant
Office actions
2
non-final + final
Responses
2
no RCE
Appeals
1
notices of appeal
Examiner
Michael G Hartley
art unit 1618 · TC 1600
Citations: 5 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20042006200820102012201420162018202020222024Owner 1Owner 2liens, releases & corrections
TitleLienReleasehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock